Cardiovascular Risk Comparison Between Expanded Hemodialysis Using Theranova and On-line Hemodiafiltration
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Feb 27, 2018
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
While conventional hemodialysis (HD) modality effectively removes small-sized molecules, performance with middle-sized and protein-bound molecules is not well established. With increasing perception on importance of middle molecule removal, on-line hemodiafiltration (HDF) is getting more attention from healthcare professionals. However, HDF has not been widely used in Korea due to its technical burden and limited public funding issue.
Novel medium cut-off (MCO) dialyzer, Theranova, is available in Korea, which showed superior performance on middle molecule removal to conventional HD and HD...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years old and older
- • Hemodialysis more than 3 months because of end-stage renal disease
- • Consent to the study protocol
- Exclusion Criteria:
- • Already receiving online hemodiafiltration before study enrollment
- • Dialysis schedule other than three times per week (e.g., once per week)
- • Receiving concurrent peritoneal dialysis
- • Having a plan to receive kidney transplantation within 1 year
- • Having multiple myeloma or monoclonal gammopathy
- • Having advanced or active malignancy
- • Having a plan to be pregnant or being pregnant / breast-feeding or not having a plan to use contraception
- • Participating in other clinical trials
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Gyeonggi Do, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Kwon Wook Joo, MD, PhD
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials